Unicycive Therapeutics, Inc. (UNCY) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Unicycive Therapeutics, Inc. (UNCY) Healthcare & Pipeline Overview

Unicycive Therapeutics, Inc. is a biotechnology firm specializing in innovative kidney disease treatments, including Renazorb for hyperphosphatemia and UNI 494 for acute kidney injury. Operating in the competitive healthcare sector, Unicycive aims to address unmet needs in chronic kidney disease management through targeted therapies.

What Is the Investment Thesis for UNCY?

Unicycive Therapeutics presents a focused investment opportunity within the biotechnology sector, targeting the underserved kidney disease market. The primary value driver is the successful clinical development and commercialization of Renazorb for hyperphosphatemia, addressing a critical need in CKD patients. Positive Phase 3 trial results and subsequent FDA approval could significantly boost the company's market capitalization. UNI 494 for AKI represents a secondary growth catalyst, offering potential upside in a separate, yet related, indication. Key risks include clinical trial failures, regulatory hurdles, and competition from existing phosphate binders. As of 2026, the company's success hinges on navigating these challenges and demonstrating the clinical and economic value of its therapies.

Based on FMP financials and quantitative analysis

UNCY Key Highlights

Unicycive is focused on developing therapies for kidney diseases, a market with significant unmet needs.

• Renazorb, the lead product candidate, targets hyperphosphatemia in chronic kidney disease patients.
• UNI 494 is being developed for the treatment of acute kidney injury.
• The company was founded in 2016 and is based in Los Altos, California.
• The company has 22 employees.

Who Are UNCY's Competitors?

UNCY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UNCY's Key Strengths?

Novel therapies targeting unmet needs in kidney disease.

• Experienced management team with expertise in drug development.
• Strong intellectual property protection for its product candidates.
• Focus on a growing market with significant potential.

What Are UNCY's Weaknesses?

Limited financial resources compared to larger pharmaceutical companies.

• Dependence on the success of its lead product candidates.
• Lack of commercial infrastructure to market and sell its products directly.
• Small number of employees.

What Could Drive UNCY Stock Higher?

Announcement of Phase 3 clinical trial results for Renazorb in hyperphosphatemia.

• Initiation of clinical trials for UNI 494 in acute kidney injury.
• Progress in securing partnerships for commercialization of Renazorb.
• Advancements in research and development of new therapies for kidney diseases.

What Are the Key Risks for UNCY?

Financial-distress signal — its Altman Z-Score of 1.26 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-88.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for Renazorb or UNI 494.
• Regulatory hurdles in obtaining approval for its products.
• Competition from existing therapies and new entrants in the kidney disease market.
• Dependence on securing additional funding to support its operations.

What Are the Growth Opportunities for UNCY?

• Expansion of Renazorb's Label: A significant growth opportunity lies in expanding the approved indications for Renazorb beyond hyperphosphatemia in CKD patients. This could involve conducting clinical trials to evaluate its efficacy in other patient populations or disease stages. Success in this area would broaden the market reach of Renazorb and increase its revenue potential. The timeline for this expansion would depend on the initiation and completion of clinical trials, potentially adding years to the company's growth trajectory.
• Commercialization Partnerships: Unicycive can leverage strategic partnerships with larger pharmaceutical companies to accelerate the commercialization of its products. Partnering with an established player would provide access to a broader sales and marketing infrastructure, enabling faster market penetration and increased sales. This approach could be particularly beneficial for Renazorb, given the established market for phosphate binders. The timeline for securing such partnerships would depend on the company's ability to demonstrate the clinical and economic value of its therapies.
• Geographic Expansion: Expanding into new geographic markets represents another growth opportunity for Unicycive. This could involve seeking regulatory approval for its products in Europe, Asia, and other regions. Entering new markets would increase the company's revenue base and diversify its geographic risk. The timeline for geographic expansion would depend on the regulatory approval process in each region, which can vary significantly.
• Development of Novel Therapies: Unicycive can continue to invest in research and development to discover and develop new therapies for kidney diseases. This could involve exploring new drug targets, developing novel drug delivery systems, or repurposing existing drugs for new indications. A successful R&D program would strengthen the company's pipeline and create new growth opportunities. The timeline for developing new therapies is inherently uncertain, but a long-term commitment to R&D is essential for sustained growth.
• Acquisition of Complementary Assets: Unicycive could pursue strategic acquisitions of companies or assets that complement its existing pipeline and expertise. This could involve acquiring companies with complementary technologies, products, or clinical programs. Acquisitions can accelerate growth by adding new revenue streams and expanding the company's capabilities. The timeline for completing acquisitions is unpredictable, but a disciplined approach to M&A can create significant value.

What Are UNCY's Competitive Advantages?

• Proprietary drug formulations: Renazorb and UNI 494 represent unique approaches to treating kidney diseases.
• Intellectual property protection: Patents and other forms of IP protect the company's products and technologies.
• Clinical expertise: Unicycive has a team of experienced scientists and clinicians with expertise in kidney disease.
• Regulatory expertise: The company has experience navigating the regulatory approval process for pharmaceutical products.

What Does UNCY Do?

Unicycive Therapeutics, Inc., established in 2016 and headquartered in Los Altos, California, is a biotechnology company dedicated to the development of innovative therapies for kidney diseases. The company focuses on addressing significant unmet needs in the treatment of chronic kidney disease (CKD) and acute kidney injury (AKI). Unicycive's lead product candidate, Renazorb, is being developed for the treatment of hyperphosphatemia in patients with CKD. Hyperphosphatemia, a condition characterized by abnormally high levels of phosphate in the blood, is a common and serious complication of CKD that can lead to cardiovascular disease, bone disease, and other health problems. Renazorb is designed to bind phosphate in the gastrointestinal tract, thereby reducing its absorption into the bloodstream. The company is also developing UNI 494 for the treatment of AKI, a sudden decline in kidney function that can result from various causes, including sepsis, surgery, and exposure to nephrotoxic drugs. UNI 494 is designed to protect kidney cells from damage and promote their recovery. Unicycive is committed to advancing the treatment of kidney diseases through the development of novel therapies that improve patient outcomes and quality of life.

What Products and Services Does UNCY Offer?

• Develop novel therapies for kidney diseases.
• Focus on addressing unmet needs in chronic kidney disease (CKD) and acute kidney injury (AKI).
• Develop Renazorb for the treatment of hyperphosphatemia in patients with CKD.
• Develop UNI 494 for the treatment of acute kidney injury.
• Conduct clinical trials to evaluate the safety and efficacy of its product candidates.
• Seek regulatory approval for its products from the FDA and other regulatory agencies.
• Commercialize its products through its own sales and marketing efforts or through partnerships.

How Does UNCY Make Money?

• Develop and commercialize pharmaceutical products for kidney diseases.
• Generate revenue through the sale of its products.
• Invest in research and development to discover and develop new therapies.
• Seek partnerships with other companies to accelerate the development and commercialization of its products.

What Industry Does UNCY Operate In?

Unicycive Therapeutics operates within the biotechnology industry, specifically targeting the kidney disease therapeutics market. This market is characterized by a growing prevalence of chronic kidney disease and acute kidney injury, driven by factors such as aging populations, diabetes, and hypertension. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing treatments for kidney diseases. Unicycive aims to differentiate itself through novel therapies that address unmet needs and improve patient outcomes.

Who Are UNCY's Key Customers?

• Patients with chronic kidney disease (CKD).
• Patients with acute kidney injury (AKI).
• Healthcare providers who treat patients with kidney diseases.
• Hospitals and clinics that provide kidney care services.

Return on equity for Unicycive Therapeutics, Inc. stands at -88.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.8%, the inverse of the P/E and a quick read on earnings relative to price.

Unicycive Therapeutics, Inc. (UNCY) Valuation Context

Valued at $146M, UNCY is classified as a micro-cap stock. Relative to its peer group, UNCY's quantitative score of 42/100 is below the peer average of 76/100.

Company Profile

Unicycive Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mountain View, US. The company is led by CEO Shalabh K. Gupta. UNCY has traded publicly since 2021.

Unicycive Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.26 places it in the distress zone, a signal of elevated financial risk.

Unicycive Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 234.5% below estimates on average.

Wall Street analysts project Unicycive Therapeutics, Inc. revenue of about $3.8M for fiscal 2026, with EPS near $-1.83. The estimate reflects 6 contributing analysts.

UNCY Financials

UNCY Latest News

UNCY Analyst Consensus

UNCY MoonshotScore

What Investors Ask About Unicycive Therapeutics, Inc. (UNCY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources